acquisition news ?
at only 800 million ??
wow imhojustsayin why do you need to respond to EVERY post on this board ??? Do you even have a job ??
look at ceo interview, posted here on the board..he does not like Horizon, which is why he rejected it. Period. It was not about the offer. He is open to other suitors, and lots others want to get into pain management to add to their portfolio. May not be $33, but high $20s easy.
don't write him off so soon..they may have another suitor that they are waiting for, and did not want to be acquired by Horizon. The poison pill was just for Horizon. Wait and see...you will be surprised.
will offer $35/sh, will be accepted.
like I said - acquisition news just out -
Drugmaker Shire to buy Baxalta for $32 billion after six-month pursuit.
when BIOs are so oversold, it takes a small bit of news and there is a strong rally. Shorts better cover....with pharma stocks down so much now, would not be surprised on merger acquisition news in the space.
what is your bottom target imho ? You earlier said 14s and then 20s. Still sticking to that. We are already mid 14s today.
nothing changed....CEO extremely bullish last call...plus even said $33 share takeout UNDERVALUES potential...with stock 35% down since last earnings, no bad news, think good time to go long into earnings.
are going to be great..nothing changed since last qtr earnings. Down today again due to CELG. Too cheap right now.
Why PT 19 when EVERY other analyst is way more bullish ? I can bet they wanted cheap shares today.
to get it cheap. EVERY other analyst has much more bullish projections for 2016 with PT over $26.
dude the entire market is going down...look at horizon, all other bios. People somehow feel if oil crashes, people will buy less pain medication !!
Low volume selloffs in a good sign. Wait for earnings and see. CEO was very bullish to reject $33 offer because he knows stock is undervalued. He is looking longer term. Obviously Horizon saw big value in DEPO long term to offer $33.
AND ignore the fool imhojustsayin...he thinks EVERY phase 1/2/3 biotech should be worth 0, because they have no revenue !!
it UNDERVALUES the value of the company...the CEO is definitely very bullish for 2016. buy low.
wow imhojustsayin you are a pest. go away. bio stocks in ph 2 are given multi billion valuations. This one deserves at least 200-300 million easy for Cebra. you are not scaring anyone. buy low.
look up info on this on the internet...this is going to be bigger than morphine. Ph 2 coming out 2016.
what a joke analysis.